Medpace Holdings Stock Fair Value – Medpace Holdings Reports Record Q4 GAAP EPS of $2.12 in 2023, Beating Expectations by $0.33.
February 20, 2023
Trending News 🌧️
Medpace Holdings ($NASDAQ:MEDP), a publicly traded clinical research organization (CRO), recently reported its Q4 GAAP earnings per share of $2.12, beating market expectations by $0.33. This marked a record quarter for the company and its stock.
Share Price
This resulted in the stock opening at $225.6 and closing at $228.8, up by 2.4% from the prior closing price of 223.5. The rise in stock prices can be attributed to the impressive financial performance for the quarter. This was driven by strong performance from their core business operations and higher client demand for their services.
This is attributed to their focus on improving operational efficiencies and cost savings initiatives, which allowed them to better manage their expenses. MEDPACE HOLDINGS is one of the leading providers of clinical development services, and their stock performance reflects their commitment to providing high quality services and innovative solutions for their clients. Their strong financial performance for the quarter indicates that they have the necessary tools and resources to deliver reliable results and drive growth in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Medpace Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 1.46k | 245.37 | 16.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Medpace Holdings. More…
| Operations | Investing | Financing |
| 388.05 | -38.74 | -775.77 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Medpace Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.35k | 966.11 | 11.25 |
Key Ratios Snapshot
Some of the financial key ratios for Medpace Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 19.2% | 29.9% | 19.1% |
| FCF Margin | ROE | ROA |
| 24.1% | 47.3% | 12.9% |
Analysis – Medpace Holdings Stock Fair Value
GoodWhale has conducted an analysis of MEDPACE HOLDINGS‘ wellbeing and has determined that the intrinsic value of its shares is around $213.4. This figure is based on GoodWhale’s proprietary Valuation Line, which considers a variety of factors such as market trends and performance to give an accurate financial picture of the company’s standing. Currently, MEDPACE HOLDINGS’ stock is traded at $228.8, suggesting that the stock is slightly overvalued by 7.2%. This analysis provides investors with valuable insight into the company’s financial health and can be used to inform decisions about whether or not to invest in MEDPACE HOLDINGS. With this data, investors can evaluate whether the current market price is a fair reflection of the company’s potential or if they should wait for a better opportunity in the future. Furthermore, since the intrinsic value of MEDPACE HOLDINGS’ stock is lower than the current market price, investors should take this into account when making an investment decision. Overall, GoodWhale’s analysis of MEDPACE HOLDINGS’ wellbeing provides valuable insight into the company’s financial health and can be used to inform investment decisions. It also highlights a potential discrepancy between the intrinsic value and the current market price for MEDPACE HOLDINGS’ stock, which should be taken into account before making an investment. More…
Peers
Medpace’s services include clinical trial management, data management, biostatistics, and medical writing. Medpace’s competitors include Icon PLC, Syneos Health Inc, and IQVIA Holdings Inc.
– Icon PLC ($NASDAQ:ICLR)
Icon PLC is a publicly traded company with a market capitalization of $14.59 billion as of March 2022. The company has a return on equity of 4.28%. Icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company has a network of over 80 sites in 40 countries. Icon’s services include clinical research, regulatory affairs, quality management, data management, and biostatistics.
– Syneos Health Inc ($NASDAQ:SYNH)
Synoes Health Inc is a pharmaceutical company with a market cap of 4.81B as of 2022. The company has a Return on Equity of 9.89%. The company develops, manufactures, and sells pharmaceutical products. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. The company operates in the United States, Europe, and Asia.
– IQVIA Holdings Inc ($NYSE:IQV)
IQVIA Holdings Inc is a global healthcare company that provides market research, data, and analytics solutions to help customers drive healthcare transformation and growth. The company’s market cap as of 2022 is 33.49B, and its ROE is 19.29%. IQVIA’s customers include healthcare payers and providers, pharmaceutical and biotech companies, and government agencies. The company’s solutions help its customers drive healthcare transformation by improving patient outcomes, reducing costs, and increasing access to care.
Summary
Medpace Holdings has seen noteworthy success in the fourth quarter of 2023, with its reported GAAP EPS of $2.12 exceeding analyst expectations by $0.33. This marks a record-high for the company and highlights the potential for growth in the coming year. Additionally, its recent strategic partnerships, technological innovation, and international expansion plans may present opportunities for those interested in investing in Medpace.
Related Posts
Recent Posts
